lanadelumab
UMCN-AKF20.04
Phase 2 mab completed
Quick answer
lanadelumab for COVID-19 is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- COVID-19
- Phase
- Phase 2
- Modality
- mab
- Status
- completed